DATA-DRIVEN DRUG DESIGN
Using the power of cutting-edge artificial intelligence (AI) to revolutionize small molecule drug design
Drug Discovery Has Changed
Designing a new drug is more challenging and complex than ever. Disease-modifying medicines for Alzheimer’s, immuno-oncology, metabolic disease or regenerative medicine require a design process that matches the complexity of the underlying biology.
The Power
Numerate has mastered the conflicting demands of complex signal processing by applying advanced, proprietary AI, evolved to use all available data – literally everything the industry currently knows, against multiple, simultaneous drug design objectives. We model real biology and apply our models at a massive scale, sifting through noise to follow signals that elude other approaches.
The Platform
Numerate has created an algorithm-centric process that drives all preclinical decisions, from hit identification through the nomination of a clinical candidate. Our platform is battle-tested and refined by a decade of experience tackling the industry’s hardest problems. It goes beyond modeling protein binding to impact the PK, ADME, and toxicity challenges of discovery.
The Promise
Numerate is applying the platform to unlock valuable biology not easily translated by the traditional approaches. Our focus is on building a valuable pipeline– on our own and through innovative collaborations with academic, government and industry partners. After all, the ultimate promise of AI-guided drug design is not just a faster, cheaper discovery process, but the delivery of better treatments for human disease.
UPCOMING EVENTS
July 25-27 in Boston, MABrandon, our CTO, will be speaking about AI from a technical perspective and Guido, our CEO, will be on a panel about how AI will accelerate and de-risk R&D.
Sept 10-13 in Basel, CHBasel Life aims to be Europe’s leading congress in the life sciences, showcasing cutting-edge science and technology. It brings together preeminent researchers in the field, and offers talented young scientists the possibility to present themselves.
Sept 18-19 in Burlingame, CALearn how the Life Science and Healthcare communities are embracing disruptive technology and machine learning to accelerate drug discovery.